<html>
<head><title>Top Documents</title></head><body style="font-family:verdana;"><h1>Topic number 0</h1><p><b>Spoligotyping of Mycobacterium tuberculosis isolates at a tertiary care hospital in India</b>   : <a href="http://dx.doi.org/10.1111/tmi.12875">10.1111_tmi.12875</a> | 1.00</p><p><b>Trends in molecular epidemiology of drug-resistant tuberculosis in Republic of Karelia, Russian Federation</b>   : <a href="http://dx.doi.org/10.1186/s12866/015/0613/3">10.1186_s12866_015_0613_3</a> | 0.93</p><p><b>Mycobacterium tuberculosis Beijing Lineage Favors the Spread of Multidrug-Resistant Tuberculosis in the Republic of Georgia</b>   : <a href="http://dx.doi.org/10.1128/JCM.00715/10">10.1128_JCM.00715_10</a> | 0.89</p><p><b>Molecular Typing of Mycobacterium Tuberculosis Complex by 24-Locus Based MIRU-VNTR Typing in Conjunction with Spoligotyping to Assess Genetic Diversity of Strains Circulating in Morocco</b>   : <a href="http://dx.doi.org/10.1371/journal.pone.0135695">10.1371_journal.pone.0135695</a> | 0.88</p><p><b>First Insight into Genetic Diversity of the Mycobacterium tuberculosis Complex in Albania Obtained by Multilocus Variable-Number Tandem-Repeat Analysis and Spoligotyping Reveals the Presence of Beijing Multidrug-Resistant Isolates</b>   : <a href="http://dx.doi.org/10.1128/JCM.02284/08">10.1128_JCM.02284_08</a> | 0.87</p><p><b>Mycobacterium tuberculosis Population in Northwestern Russia: An Update from Russian-EU/Latvian Border Region</b>   : <a href="http://dx.doi.org/10.1371/journal.pone.0041318">10.1371_journal.pone.0041318</a> | 0.86</p><p><b>Spoligotyping and drug resistance patterns of Mycobacterium tuberculosis isolates from five provinces of Iran</b>   : <a href="http://dx.doi.org/10.1002/mbo3.139">10.1002_mbo3.139</a> | 0.85</p><p><b>Genetic Diversity and Drug Susceptibility of Mycobacterium tuberculosis Isolates from Zunyi, One of the Highest-Incidence-Rate Areas in China</b>   : <a href="http://dx.doi.org/10.1128/JCM.06095/11">10.1128_JCM.06095_11</a> | 0.84</p><p><b>Spoligotype-Based Comparative Population Structure Analysis of Multidrug-Resistant and Isoniazid-Monoresistant Mycobacterium tuberculosis Complex Clinical Isolates in Poland</b>   : <a href="http://dx.doi.org/10.1128/JCM.00572/10">10.1128_JCM.00572_10</a> | 0.81</p><p><b>Molecular snapshot of Mycobacterium tuberculosis population in Kazakhstan: A country-wide study</b>   : <a href="http://dx.doi.org/10.1016/j.tube.2015.04.012">10.1016_j.tube.2015.04.012</a> | 0.80</p><p><b>Tuberculous Spondylitis in Russia and Prominent Role of Multidrug-Resistant Clone Mycobacterium tuberculosis Beijing B0/W148</b>   : <a href="http://dx.doi.org/10.1128/AAC.04221/14">10.1128_AAC.04221_14</a> | 0.79</p><p><b>Time to initiation of multidrug-resistant tuberculosis treatment and its relation with outcome in a high incidence district in Lima, Peru</b>   : <a href="http://dx.doi.org/10.1111/tmi.12430">10.1111_tmi.12430</a> | 0.78</p><p><b>Genetic diversity of multidrug-resistant tuberculosis in a resource-limited region of China</b>   : <a href="http://dx.doi.org/10.1016/j.ijid.2014.05.020">10.1016_j.ijid.2014.05.020</a> | 0.77</p><p><b>Genetic diversity and molecular epidemiology of multidrug-resistant Mycobacterium tuberculosis in Minas Gerais State, Brazil</b>   : <a href="http://dx.doi.org/10.1186/s12879/015/1057/y">10.1186_s12879_015_1057_y</a> | 0.75</p><p><b>Haarlem 3 is the predominant genotype family in multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis in the capital of Iran: A 5-year survey</b>   : <a href="http://dx.doi.org/10.1016/j.jgar.2016.01.007">10.1016_j.jgar.2016.01.007</a> | 0.75</p><h1>Topic number 1</h1><p><b>Insights into RpoB clinical mutants in mediating rifampicin resistance in Mycobacterium tuberculosis</b>   : <a href="http://dx.doi.org/10.1016/j.jmgm.2016.04.005">10.1016_j.jmgm.2016.04.005</a> | 1.00</p><p><b>Ion Channel Blockers as Antimicrobial Agents, Efflux Inhibitors, and Enhancers of Macrophage Killing Activity against Drug Resistant Mycobacterium tuberculosis</b>   : <a href="http://dx.doi.org/10.1371/journal.pone.0149326">10.1371_journal.pone.0149326</a> | 1.00</p><p><b>RNA expression analysis of efflux pump genes in clinical isolates of multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis in South Korea</b>   : <a href="http://dx.doi.org/10.1016/j.meegid.2017.01.002">10.1016_j.meegid.2017.01.002</a> | 1.00</p><p><b>Interplay between Mutations and Efflux in Drug Resistant Clinical Isolates of Mycobacterium tuberculosis</b>   : <a href="http://dx.doi.org/10.3389/fmicb.2017.00711">10.3389_fmicb.2017.00711</a> | 1.00</p><p><b>Mutations in gyrA and gyrB among Fluoroquinolone- and Multidrug-Resistant Mycobacterium tuberculosis Isolates</b>   : <a href="http://dx.doi.org/10.1128/AAC.01049/15">10.1128_AAC.01049_15</a> | 0.99</p><p><b>Docking studies on novel analogues of 8 methoxy fluoroquinolones against GyrA mutants of Mycobacterium tuberculosis</b>   : <a href="http://dx.doi.org/10.1186/1472/6807/11/47">10.1186_1472_6807_11_47</a> | 0.99</p><p><b>New Insights into Fluoroquinolone Resistance in Mycobacterium tuberculosis: Functional Genetic Analysis of gyrA and gyrB Mutations</b>   : <a href="http://dx.doi.org/10.1371/journal.pone.0039754">10.1371_journal.pone.0039754</a> | 0.99</p><p><b>Detection of novel coupled mutations in the katG gene (His276Met, Gln295His and Ser315Thr) in a multidrug-resistant Mycobacterium tuberculosis strain from Chennai, India, and insight into the molecular mechanism of isoniazid resistance using structural bioinformatics approaches</b>   : <a href="http://dx.doi.org/10.1016/j.ijantimicag.2010.11.023">10.1016_j.ijantimicag.2010.11.023</a> | 0.99</p><p><b>Genetic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates in Hong Kong</b>   : <a href="http://dx.doi.org/10.1093/jac/dkm054">10.1093_jac_dkm054</a> | 0.99</p><p><b>Contribution of Efflux to the Emergence of Isoniazid and Multidrug Resistance in Mycobacterium tuberculosis</b>   : <a href="http://dx.doi.org/10.1371/journal.pone.0034538">10.1371_journal.pone.0034538</a> | 0.99</p><p><b>Second-line anti-tuberculosis drug resistance and its genetic determinants in multidrug-resistant Mycobacterium tuberculosis clinical isolates</b>   : <a href="http://dx.doi.org/10.1016/j.jmii.2015.04.003">10.1016_j.jmii.2015.04.003</a> | 0.99</p><p><b>Interactions of linezolid and second-line anti-tuberculosis agents against multidrug-resistant Mycobacterium tuberculosis in vitro and in vivo</b>   : <a href="http://dx.doi.org/10.1016/j.ijid.2016.08.027">10.1016_j.ijid.2016.08.027</a> | 0.99</p><p><b>High Level of Cross-Resistance between Kanamycin, Amikacin, and Capreomycin among Mycobacterium tuberculosis Isolates from Georgia and a Close Relation with Mutations in the rrs Gene</b>   : <a href="http://dx.doi.org/10.1128/AAC.00851/09">10.1128_AAC.00851_09</a> | 0.99</p><p><b>Genotypic Analysis of Genes Associated with Independent Resistance and Cross-Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis Clinical Isolates</b>   : <a href="http://dx.doi.org/10.1128/AAC.01028/15">10.1128_AAC.01028_15</a> | 0.99</p><p><b>In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages</b>   : <a href="http://dx.doi.org/10.1007/s002849900095">10.1007_s002849900095</a> | 0.99</p><h1>Topic number 2</h1><p><b>Multidrug-resistant tuberculosis</b>   : <a href="http://dx.doi.org/10.1186/1471/2334/8/10">10.1186_1471_2334_8_10</a> | 1.00</p><p><b>Are scientific research outputs aligned with national policy makers' priorities? A case study of tuberculosis in Cambodia</b>   : <a href="http://dx.doi.org/10.1093/heapol/czx041">10.1093_heapol_czx041</a> | 1.00</p><p><b>The making of a public health problem: multi-drug resistant tuberculosis in India</b>   : <a href="http://dx.doi.org/10.1093/heapol/czs069">10.1093_heapol_czs069</a> | 0.99</p><p><b>Financial resources required for tuberculosis control to achieve global targets set for 2015</b>   : <a href="http://dx.doi.org/10.2471/BLT.07.049767">10.2471_BLT.07.049767</a> | 0.99</p><p><b>Beyond DOTS: Avenues ahead in the management of tuberculosis</b>   : <a href="http://dx.doi.org/pub-1933">pub-1933</a> | 0.99</p><p><b>Tuberculosis in complex emergencies</b>   : <a href="http://dx.doi.org/10.2471/BLT.06.037630">10.2471_BLT.06.037630</a> | 0.99</p><p><b>Assessment of tuberculosis burden in China using a dynamic disease simulation model</b>   : <a href="http://dx.doi.org/10.5588/ijtld.12.0959">10.5588_ijtld.12.0959</a> | 0.99</p><p><b>Tuberculosis 2013:5 Drug-resistant tuberculosis: time for visionary political leadership</b>   : <a href="http://dx.doi.org/10.1016/S1473/3099/13/70030/6">10.1016_S1473_3099_13_70030_6</a> | 0.99</p><p><b>Why healthcare workers are sick of TB</b>   : <a href="http://dx.doi.org/10.1016/j.ijid.2014.12.003">10.1016_j.ijid.2014.12.003</a> | 0.99</p><p><b>Epidemiology and control of tuberculosis in Western European cities</b>   : <a href="http://dx.doi.org/pub-1944">pub-1944</a> | 0.99</p><p><b>Epidemiology of tuberculosis in Chongqing, China: a secular trend from 1992 to 2015</b>   : <a href="http://dx.doi.org/10.1038/s41598/017/07959/2">10.1038_s41598_017_07959_2</a> | 0.99</p><p><b>Drug partnerships and global practices</b>   : <a href="http://dx.doi.org/10.1016/j.healthplace.2011.05.004">10.1016_j.healthplace.2011.05.004</a> | 0.99</p><p><b>Tuberculosis. Digging deep in the soul of humanity</b>   : <a href="http://dx.doi.org/10.1016/j.rmed.2016.08.009">10.1016_j.rmed.2016.08.009</a> | 0.99</p><p><b>What's new in TB?</b>   : <a href="http://dx.doi.org/pub-1579">pub-1579</a> | 0.99</p><p><b>Tuberculosis - a missed opportunity?</b>   : <a href="http://dx.doi.org/10.7861/clinmedicine.2/1/55">10.7861_clinmedicine.2_1_55</a> | 0.99</p><h1>Topic number 3</h1><p><b>Xpert MTB/RIF assay for diagnosis of pulmonary tuberculosis in sputum specimens in remote health care facility</b>   : <a href="http://dx.doi.org/10.1186/s12866/015/0566/6">10.1186_s12866_015_0566_6</a> | 1.00</p><p><b>Direct Nitrate Reductase Assay versus Microscopic Observation Drug Susceptibility Test for Rapid Detection of MDR-TB in Uganda</b>   : <a href="http://dx.doi.org/10.1371/journal.pone.0019565">10.1371_journal.pone.0019565</a> | 0.99</p><p><b>Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa</b>   : <a href="http://dx.doi.org/10.1164/rccm.200709/1436OC">10.1164_rccm.200709_1436OC</a> | 0.99</p><p><b>Multicenter Noninferiority Evaluation of Hain GenoType MTBDRplus Version 2 and Nipro NTM plus MDRTB Line Probe Assays for Detection of Rifampin and Isoniazid Resistance</b>   : <a href="http://dx.doi.org/10.1128/JCM.00251/16">10.1128_JCM.00251_16</a> | 0.99</p><p><b>A suggested algorithm for detection of multi drug-resistant tuberculosis in Zimbabwe</b>   : <a href="http://dx.doi.org/10.3855/jidc.8009">10.3855_jidc.8009</a> | 0.99</p><p><b>Evaluation of seven tests for the rapid detection of multidrug-resistant tuberculosis in Uganda</b>   : <a href="http://dx.doi.org/pub-1471">pub-1471</a> | 0.99</p><p><b>Evaluation of the microscopic observational drug susceptibility assay for rapid and efficient diagnosis of multi-drug resistant tuberculosis</b>   : <a href="http://dx.doi.org/10.4103/0255/0857.93039">10.4103_0255_0857.93039</a> | 0.99</p><p><b>Microscopic observation drug susceptibility assay in the diagnosis of multidrug-resistant tuberculosis</b>   : <a href="http://dx.doi.org/10.5588/ijtld.11.0547">10.5588_ijtld.11.0547</a> | 0.99</p><p><b>Rapid detection of Mycobacterium tuberculosis and rifampicin resistance in extrapulmonary tuberculosis and sputum smear-negative pulmonary suspects using Xpert MTB/RIF</b>   : <a href="http://dx.doi.org/10.1099/jmm.0.000449">10.1099_jmm.0.000449</a> | 0.99</p><p><b>Evaluation of the GenoType (R) MTBDRplus line probe assay on sputum-positive samples in routine settings in China</b>   : <a href="http://dx.doi.org/10.5588/ijtld.13.0857">10.5588_ijtld.13.0857</a> | 0.99</p><p><b>Microscopic-observation drug susceptibility assay provides rapid and reliable identification of MDR-TB</b>   : <a href="http://dx.doi.org/pub-1713">pub-1713</a> | 0.99</p><p><b>Rapid detection of rifampicin and isoniazid resistance in Mycobacterium tuberculosis by the direct thin-layer agar method</b>   : <a href="http://dx.doi.org/pub-1645">pub-1645</a> | 0.99</p><p><b>Field assessment of the direct nitrate reductase assay for rapid detection of multidrug-resistant tuberculosis in Honduras</b>   : <a href="http://dx.doi.org/10.5588/ijtld.10.0697">10.5588_ijtld.10.0697</a> | 0.99</p><p><b>Evaluation of the resazurin microtiter assay for rapid detection of of loxacin resistance in M-tuberculosis</b>   : <a href="http://dx.doi.org/pub-1816">pub-1816</a> | 0.98</p><p><b>Evaluation of the Genotype (R) MTBDRplus assay as a tool for drug resistance surveys</b>   : <a href="http://dx.doi.org/10.5588/ijtld.10.0515">10.5588_ijtld.10.0515</a> | 0.98</p><h1>Topic number 4</h1><p><b>Evaluation of T cell immune responses in multi-drug-resistant tuberculosis (MDR-TB) patients to Mycobacterium tuberculosis total tipid antigens</b>   : <a href="http://dx.doi.org/10.1111/j.1365/2249.2007.03406.x">10.1111_j.1365_2249.2007.03406.x</a> | 0.92</p><p><b>IL-10 and IL-12 Production in Response to Mycobacterium Tuberculosis Total Lipid Antigens in Multidrug-Resistant Tuberculosis</b>   : <a href="http://dx.doi.org/pub-1509">pub-1509</a> | 0.92</p><p><b>Esophagomediastinal Fistula Secondary to Multidrug-resistant Tuberculous Mediastinal Lymphadenitis</b>   : <a href="http://dx.doi.org/10.2169/internalmedicine.53.2145">10.2169_internalmedicine.53.2145</a> | 0.86</p><p><b>The production of tumour necrosis factor-alpha is decreased in peripheral blood mononuclear cells from multidrug-resistant tuberculosis patients following stimulation with the 30-kDa antigen of Mycobacterium tuberculosis</b>   : <a href="http://dx.doi.org/10.1046/j.1365/2249.2003.02172.x">10.1046_j.1365_2249.2003.02172.x</a> | 0.85</p><p><b>Tumor necrosis factor-alpha and interleukin-10 in whole blood is associated with disease progression in pulmonary mulitdrug-resistant tuberculosis patients</b>   : <a href="http://dx.doi.org/10.1159/000113932">10.1159_000113932</a> | 0.82</p><p><b>Cellular responses to MPT-51, GlcB and ESAT-6 among MDR-TB and active tuberculosis patients in Brazil</b>   : <a href="http://dx.doi.org/10.1016/j.tube.2008.06.002">10.1016_j.tube.2008.06.002</a> | 0.80</p><p><b>Mycobacterium tuberculosis induces high production of nitric oxide in coordination with production of tumour necrosis factor-alpha in patients with fresh active tuberculosis but not in MDR tuberculosis</b>   : <a href="http://dx.doi.org/10.1111/j.1440/1711.2004.01245.x">10.1111_j.1440_1711.2004.01245.x</a> | 0.78</p><p><b>Levels of tumour necrosis factor-alpha and IL-1a in newly diagnosed and multidrug resistant tuberculosis</b>   : <a href="http://dx.doi.org/10.1111/j.1440/1843.2005.00711.x">10.1111_j.1440_1843.2005.00711.x</a> | 0.76</p><p><b>rhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placebo</b>   : <a href="http://dx.doi.org/10.1016/S0962/8479/97/90026/5">10.1016_S0962_8479_97_90026_5</a> | 0.76</p><p><b>Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol</b>   : <a href="http://dx.doi.org/10.1016/S0140/6736/96/12273/X">10.1016_S0140_6736_96_12273_X</a> | 0.74</p><p><b>Preparation and in Vivo evaluation of a dry powder for inhalation of capreomycin</b>   : <a href="http://dx.doi.org/10.1007/s11095/007/9381/6">10.1007_s11095_007_9381_6</a> | 0.73</p><p><b>Dry Powder PA-824 Aerosols for Treatment of Tuberculosis in Guinea Pigs</b>   : <a href="http://dx.doi.org/10.1128/AAC.01471/09">10.1128_AAC.01471_09</a> | 0.72</p><p><b>Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model</b>   : <a href="http://dx.doi.org/10.1128/AAC.01164/06">10.1128_AAC.01164_06</a> | 0.71</p><p><b>CLINICAL AND IMMUNE-RESPONSES OF TUBERCULOSIS PATIENTS TREATED WITH LOW-DOSE IL-2 AND MULTIDRUG THERAPY</b>   : <a href="http://dx.doi.org/pub-2086">pub-2086</a> | 0.70</p><p><b>Enrichment of regulatory T-cells in blood of patients with multidrug-resistant tuberculosis</b>   : <a href="http://dx.doi.org/10.5588/ijtld.15.0148">10.5588_ijtld.15.0148</a> | 0.69</p><h1>Topic number 5</h1><p><b>Psychological distress and its effect on tuberculosis treatment outcomes in Ethiopia</b>   : <a href="http://dx.doi.org/10.3402/gha.v8.29019">10.3402_gha.v8.29019</a> | 1.00</p><p><b>Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China</b>   : <a href="http://dx.doi.org/10.1186/s12879/017/2662/8">10.1186_s12879_017_2662_8</a> | 1.00</p><p><b>Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort</b>   : <a href="http://dx.doi.org/10.1186/s40360/015/0036/7">10.1186_s40360_015_0036_7</a> | 1.00</p><p><b>Predictors of unsuccessful interim treatment outcomes of multidrug resistant tuberculosis patients</b>   : <a href="http://dx.doi.org/10.1186/s12879/017/2746/5">10.1186_s12879_017_2746_5</a> | 1.00</p><p><b>Treatment outcomes in multidrug resistant tuberculosis-human immunodeficiency virus Co-infected patients on anti-retroviral therapy at Sizwe Tropical Disease Hospital Johannesburg, South Africa</b>   : <a href="http://dx.doi.org/10.1186/s12879/015/1214/3">10.1186_s12879_015_1214_3</a> | 1.00</p><p><b>Patterns of Treatment Interruption among Patients with Multidrug-Resistant TB (MDR TB) and Association with Interim and Final Treatment Outcomes</b>   : <a href="http://dx.doi.org/10.1371/journal.pone.0070064">10.1371_journal.pone.0070064</a> | 1.00</p><p><b>Determinants of multidrug-resistant tuberculosis in patients who underwent first-line treatment in Addis Ababa: a case control study</b>   : <a href="http://dx.doi.org/10.1186/1471/2458/13/782">10.1186_1471_2458_13_782</a> | 1.00</p><p><b>Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients</b>   : <a href="http://dx.doi.org/10.1371/journal.pmed.1001300">10.1371_journal.pmed.1001300</a> | 1.00</p><p><b>Outcomes of Multi-Drug Resistant Tuberculosis (MDR-TB) among a Cohort of South African Patients with High HIV Prevalence</b>   : <a href="http://dx.doi.org/10.1371/journal.pone.0020436">10.1371_journal.pone.0020436</a> | 1.00</p><p><b>Alcohol, Hospital Discharge, and Socioeconomic Risk Factors for Default from Multidrug Resistant Tuberculosis Treatment in Rural South Africa: A Retrospective Cohort Study</b>   : <a href="http://dx.doi.org/10.1371/journal.pone.0083480">10.1371_journal.pone.0083480</a> | 1.00</p><p><b>Risk factors associated with default, failure and death among tuberculosis patients treated in a DOTS programme in Tiruvallur District, South India, 2000</b>   : <a href="http://dx.doi.org/pub-1972">pub-1972</a> | 1.00</p><p><b>Treatment Outcomes in Tuberculosis Patients with Diabetes: A Polytomous Analysis Using Brazilian Surveillance System</b>   : <a href="http://dx.doi.org/10.1371/journal.pone.0100082">10.1371_journal.pone.0100082</a> | 0.99</p><p><b>Ambulatory-Based Standardized Therapy for Multi-Drug Resistant Tuberculosis: Experience from Nepal, 2005-2006</b>   : <a href="http://dx.doi.org/10.1371/journal.pone.0008313">10.1371_journal.pone.0008313</a> | 0.99</p><p><b>Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru.</b>   : <a href="http://dx.doi.org/10.1056/NEJMoa022928">10.1056_NEJMoa022928</a> | 0.99</p><p><b>Pulmonary resection in the treatment of 43 patients with well-localized, cavitary pulmonary multidrug-resistant tuberculosis in Shanghai</b>   : <a href="http://dx.doi.org/10.1093/icvts/ivt251">10.1093_icvts_ivt251</a> | 0.99</p></body></html>